Sugi Predict

Sugi Predict / Compounds / SCHEMBL2939650

SCHEMBL2939650

SCHEMBL2939650

CC1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc(C(=O)Oc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 4/20 0.58
▸ SMO Q99835 4/20 0.43
▸ PTGDR2 Q9Y5Y4 1/20 0.35
▸ TP53 P04637 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ TAS2R8 Q9NYW2 2/20 0.33
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940885 0.88 SMO (0.45) IGF1RSMOTP53HCRTR1HCRTR2
SCHEMBL2942468 0.88 IGF1R (0.61) IGF1RSMOPTGDR2TAS2R8
SCHEMBL2936925 0.88 IGF1R (0.56) IGF1RSMOPTGDR2TP53TAS2R8
SCHEMBL3733461 0.88 IGF1R (0.56) IGF1RSMOPTGDR2GAATAS2R8
SCHEMBL2938684 0.87 IGF1R (0.56) IGF1RSMOTP53GAALMNA
SCHEMBL2938849 0.86 IGF1R (0.61) IGF1RSMOPTGDR2GAATAS2R8
SCHEMBL2934701 0.86 IGF1R (0.50) IGF1RSMO
SCHEMBL2940402 0.86 IGF1R (0.59) IGF1RSMOGAALMNAMAPK1
SCHEMBL2937190 0.85 IGF1R (0.58) IGF1RSMOPTGDR2LMNATAS2R8
SCHEMBL2938845 0.85 IGF1R (0.62) IGF1RSMOTAS2R8HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885SMO 2187/4885PTGDR2 3179/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885SMO 2697/4885PTGDR2 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.